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Background: Borrelia miyamotoi is a relapsing fever spirochete found in Ixodes ticks in North America, Europe, and
Asia, and has recently been found to be invasive in humans. Cultivation of this spirochete has not yet been
described, but is important for patient diagnostics and scientific purposes. Host specificity of Borrelia species is
dependent on resistance to host complement (serum resistance), and since B. miyamotoi has been identified as a
human pathogen we were interested whether B. miyamotoi is resistant to human complement.
Methods: We inoculated B. miyamotoi strains LB-2001 and HT31 in modified-Kelly-Pettenkofer medium with 10%
fetal calf serum (MKP-F), and used standard non-laborious Borrelia culture methods to culture the spirochetes. Next,
we assessed serum sensitivity by a direct killing assay and a growth inhibition assay.
Results: We were able to passage B. miyamotoi over 10 times using a standard culture method in MKP-F medium,
and found B. miyamotoi to be resistant to human complement. In contrast to B. miyamotoi, Borrelia anserina - a
relapsing fever spirochete unrelated to human infection- was serum sensitive.
Conclusions: Using a variation on MKP medium we were able to culture B. miyamotoi, opening the door to in vitro
research into this spirochete. In addition, we describe that B. miyamotoi is resistant to human complement, which
might play an important role in pathogenesis. We have also found B. anserina to be sensitive to human
complement, which might explain why it is not related to human infection. Summarizing, we describe a novel
culture method for B. miyamotoi and show it is resistant to human complement.
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Borrelia miyamotoi is a relapsing fever spirochete first
discovered in Ixodes persulcatus ticks in Hokkaido,
Japan [1], which over the years has been found across
North- America in Ixodes pacificus and Ixodes scapu-
laris ticks [2,3] and Europe [4], where it has been identi-
fied in Ixodes ricinus ticks. The first human cases of B.
miyamotoi infection have only recently been identified
in Russia [5], and together with studies performed in
the U.S.A. [6,7], demonstrated a clinical picture of a fe-
brile viral-like illness several weeks after a tick-bite. In* Correspondence: lyme@amc.uva.nl
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article, unless otherwise stated.two patients with severe immunodeficiency, B. miyamo-
toi infection was found to cause a meningoencephalitis
[8,9]. Detection of B. miyamotoi infection in patients
and ticks is mostly performed by PCR for the 16S rRNA
gene, flagellin or the GLPQ gene. Serology is currently
based on detection of anti-GLPQ antibodies. While
Asian B. miyamotoi strains have been isolated using
BSK-II medium [1], there are no reports describing its
consistent in vitro propagation. In addition, established
methods for propagating the North-American strain
LB-2001 rely on intraperitoneal inoculation in SCID
mice and this strain in particular is considered to be un-
cultivable [10]. For both diagnostic and scientific pur-
poses a practical and non-laborious culture method for
this relatively unknown spirochete should be estab-
lished. This method should ideally not differ much fromentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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and B. burgdorferi sensu lato spirochetes. We have
tested multiple culture media modifications and here
we describe one in particular that allowed us to culture
B. miyamotoi in a medium and method that also readily
propagates various other Borrelia spirochetes. Serum
sensitivity differs greatly amongst relapsing fever as well
as B. burgdorferi sensu lato species, and is thought to be
important in its ecology, capacity to invade different
hosts and human pathogenesis [11]. Since we were now
able to culture B. miyamotoi, we explored the suscepti-




B. miyamotoi strain LB-2001 was derived from I. scapu-
laris ticks in the U.S.A. [2] and had been propagated
through intraperitoneal inoculation of SCID mice ap-
proximately ten times since its isolation from a tick. B.
miyamotoi-infected plasma from a SCID mouse was
kindly provided by Durland Fish and Linda Bockenstedt,
Yale University. B. miyamotoi strain HT31 was isolated in
BSK-II medium from an I. persulcatus tick in Japan [1]
and a low-passage (less than 5) isolate was provided by
Barbara Johnson, CDC through Volker Fingerle, German
National Reference Centre for Borrelia. Low-passage (less
than 5 passages since their isolation) B. hermsii HS1 [12],
B. anserina Ni-NL [13,14] and B. garinii strain A87S [15]
were cultured from −80°C glycerolpeptone stocks. High-
passage (more than 20) reference strain B. afzelii PKo
[16,17] was inoculated in a C3H mouse through intrader-
mal syringe injection and a low-passage (less than 5) blad-
der isolate was cultured from −80°C glycerolpeptone
stocks for in vitro experiments.
Description of culture medium and culture conditions
The culture medium we used for culturing B. miyamotoi
is a variation on modified Kelly-Pettenkofer Medium, des-
ignated MKP-F. One liter of medium is prepared as fol-
lows: First, 162.8 ml Milli-Q water, 65.1 ml 10× CMRL
1066 without glutamine (Life technologies, Carlsbad, CA,
U.S.A.), 44.8 ml heat-inactivated rabbit serum (Biotrading,
Mijdrecht, The Netherlands), 3.9 g of HEPES (Sigma-
Aldrich, St. Louis, MO, U.S.A.), 3.3 g of glucose (Sigma-
Aldrich), 2.0 g of Neopeptone (BD biosciences, Franklin
lakes, NJ, U.S.A.), 1.4 g of sodium bicarbonate (Sigma-
Aldrich), 523 mg of Sodium pyruvate (Merck Millipore,
Billerica, MA, U.S.A.), 458 mg of sodium citrate (Sigma-
Aldrich), and 261 mg of N-acetyl-glucosamine (Sigma-
Aldrich) were prepared, set to pH 7.6 by adding 10 N
NaOH (Merck Millipore), and filtered using a 0.2 μm
filter. Next, 500 ml of 65.57 g/L bovine serum albumin
(Sigma-Aldrich) in Milli-Q water (filtered and pH set to 7.6)was added. Finally, 127.3 ml of autoclaved 7% gelatin
(Oxoid, Thermo Scientific, Waltham, MA, U.S.A.) set to
pH 7.7 and 100 ml heat-inactivated fetal calf serum
(BioWhittaker- Lonza, Basel, Switzerland) were added.
Seven milliliter aliquots in nine milliliter sterile glass
tubes (VSM, Andeville, France) were stored at −20°C
until use. A total of 500 μl of plasma from an LB-2001
infected SCID mouse or from medium containing B.
miyamotoi HT31 was added to room-temperature
MKP-F medium and capped tubes were incubated in a
33°C incubator (Memmert, Schwabach, Germany), cre-
ating a microaerophilic environment. After 6–8 days
cultures had reached approximately 1–2 × 107/ml) and
were subsequently passaged at 1:5 or 1:10 dilution for
P2, 1:25 for P3 and 1:100 for all subsequent passages, or
aliquotted and stored at −80°C in 4% glycerolpeptone.
Spirochetes were enumerated directly as described previ-
ously [17], using dark-field microscopy on 5 μl samples by
counting at least 5 fields at a 250x magnification. A total
of 350 μl of cerebrospinal fluid (CSF) - that had been
stored at −80°C for two years - from a previously de-
scribed patient [9] was cultured in MKP-F and checked
for the presence of viable spirochetes for 6 weeks, using
dark-field microscopy.
Serum sensitivity
All strains were cultured at 33°C using the above men-
tioned culture medium until they reached a concentra-
tion of 1-2×107/ml, counted as described before [18].
For normal human serum (NHS) we pooled serum sam-
ples from 4 healthy individuals (stored in −80°C) in
equal ratios, and heat-inactivated serum (HIS) was gener-
ated by incubating NHS at 56°C for 45 minutes. Serum
samples were checked for the absence of Borrelia burgdor-
feri s.l. antibodies using a C6 EIA (Immunetics, Boston,
MA, U.S.A.) and all were negative. In a 96-well V-shaped
cell culture plate (Greiner bio-one, Kremsmünster,
Austria) 25 μl of the spirochete culture and 25 μl of NHS
or HIS were mixed and the plate was sealed and incubated
at 37°C. After one and three hours, wells were resuspended
and 5 μl of the samples were analyzed under dark-field mi-
croscopy. Samples were blinded and 100 spirochetes per
sample were designated as either motile or immotile, as de-
scribed previously [19]. Another method to assess serum
sensitivity was performed using a pH indicator, based on
previous studies in other Borrelia species [19-21]. In short,
5x106 mid-log phase (1-2×107/ml) B. miyamotoi LB-2001,
B. miyamotoi HT31, B. garinii A87S and B. anserina spiro-
chetes were washed in PBS, resuspended in 50 μl MKP-F
medium containing a final phenol red concentration of
240 μg/ml, rifampicine (50 μg/ml) and phosphomycin
(100 μg/ml). Samples were mixed with 50 μl pooled
NHS or 50 μl HIS and cultured in sealed microtiter plates
at 33°C for multiple days during which absorbance was
Table 2 Peak densities and motility in serial passages of
B. miyamotoi in MKP-F medium
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reader (BioTek instruments inc., Winooski, VT, U.S.A.).Passage Peak density# Motility*
LB-2001 HT31 LB-2001 HT31
1 12.51 1.91 901 1001
2 15.2 (2.3)2 14.2 (4.2)3 100 (0)2 96.7 (3.3)3
3 21.6 (0.9)2 14.8 (4.7)3 100 (0)2 100 (0)3
4 14.4 (0.6)2 22.3 (5.5)3 100 (0)2 100 (0)3
5 18.1 (4.4)2 15.8 (4.9)3 100 (0)2 100 (0)3
6 11.6 (0.3)2 20.2 (4.2)3 100 (0)2 96.7 (3.3)3
7 15.0 (1.3)2 21.9 (4.5)3 100 (0)2 100 (0)3
8 20.0 (2.5)2 19.6 (6.0)3 100 (0)2 100 (0)3
9 19.1 (9.1)2 24.0 (7.8)3 100 (0)2 100 (0)3
2 3 2 3Statistical analysis
A Kruskal-Wallis test was performed to identify a differ-
ence in motility between different Borrelia strains and
conditions. The significance of the difference between
two conditions (normal human serum versus heat-
inactivated serum) for each Borrelia genospecies was ana-
lyzed using a two-tailed Mann–Whitney test. Optical
densometry curves were compared using a repeated mea-
sures ANOVA. All analyses were performed using Prism
5.0 software (GraphPad Software, San Diego, CA) and p <
0.05 was considered significant.10 16.9 (5.6) 17.7 (4.5) 100 (0) 100 (0)
B. miyamotoi strains LB-2001 and HT31 were successfully passaged to P10
multiple times. #Mean (±SEM) ×106 spirochetes/ml as determined by dark-field
microscopy. *Motility is depicted as the mean percentage of motile spirochetes
(±SEM). The number of individual cultures is depicted in superscript.Results
Culturing B. miyamotoi
Using a variation on Modified Kelly-Pettenkofer Medium,
containing 10% FCS and designated MKP-F (Table 1), we
managed to culture B. miyamotoi LB-2001 and B. miya-
motoi strain HT31 in a similar fashion as we culture B.
burgdorferi sensu lato in our laboratory. Using 7 ml of
medium in 9 ml glass tubes in a 33°C incubator, we were
able to consistently grow B. miyamotoi to a concentration
of 1–2 × 107/ml for 10 passages (Table 2), as well as culture
B. miyamotoi from glycerolpeptone stocks stored at −80°C.
In addition, there was morphologically no difference in
spirochete viability and motility throughout passages as
assessed by dark-field microscopy. However, a frozen CSF
sample from a patient with B. miyamotoi meningoenceph-
alitis remained negative after 6 weeks of cultivation.Table 1 Comparison of medium ingredients between
MKP-F and the MKP medium it is based upon
MKP-F Per liter MKP Per liter
MilliQ 662.8 ml MilliQ 670 ml
7% gelatine 127.3 ml 7% gelatine 149 ml
FCS 100 ml -
10× CMRL 65.1 ml 10x CMRL 74.5 ml
Rabbit serum 44.8 ml Rabbit serum 53.6 ml
BSA 32.8 g BSA 52.2 ml
HEPES 3.9 g HEPES 4.5 g
Glucose 3.3 g Glucose 2.2 g
Neopeptone 2.0 g Neopeptone 3.7 g
Sodium bicarbonate 1.4 g Sodium bicarbonate 1.5 g
Sodium citrate 0.5 g Sodium citrate 0.5 g
Sodium pyruvate 0.5 g Sodium pyruvate 0.6 g
N-acetyl glucosamine 0.3 g N-acetyl glucosamine 0.3 gSerum sensitivity
As humans have been infected by B. miyamotoi, we hy-
pothesized the spirochete to be resistant to human com-
plement. In order to evaluate serum sensitivity we grew
B. miyamotoi LB-2001 and HT31 spirochetes to a con-
centration of 1-2x107/ml and assessed spirochete motil-
ity one and three hours after addition of 50% pooled
normal human serum (NHS). As a control, we added
Heat Inactivated Serum (HIS), in which the complement
was inactivated at 56°C. Indeed, at both time points there
was no significant decrease in B. miyamotoi motility after
addition of NHS as compared to HIS, indicating B. miya-
motoi is resistant to human serum. As expected, B. afzelii
PKo and B. hermsii, a Lyme borreliosis spirochete and re-
lapsing fever spirochete respectively, were also resistant to
killing by human complement (Figure 1A). In contrast, B.
garinii A87S, a serum sensitive Lyme borreliosis spiro-
chete, and B. anserina, a spirochete from the relapsing
fever clade causing avian borreliosis, both showed a trend
towards loss of motility after incubation with NHS com-
pared to HIS (p = 0.08). We confirmed our findings using
a pH-based growth inhibition assay (Figure 1B). In this
pH-based assay growth of B. miyamotoi strains LB-2001
and HT31, represented by a pH-dependent decrease in
OD, was similar when 50% normal human serum or 50%
heat-inactivated human serum were added (p = 0.39 and
p = 0.99, respectively). In contrast, B. garinii A87S and B.
anserina did not grow in the presence of normal human
serum while growth in heat-inactivated serum was un-
affected (both p ≤ 0.0001, B. garinii data not shown). This
clearly indicates that both B. miyamotoi strains are serum
resistant, whereas B. anserina is serum sensitive. Negative
controls (culture medium without spirochetes added) did
not show a reduced OD over time (data not shown).
Figure 1 Serum sensitivity: comparing motility and growth in normal human serum (NHS) versus heat-inactivated serum (HIS). A.
Direct killing assay. Six different Borrelia species were subjected to 50% pooled NHS or 50% pooled HIS: B. afzelii strain PKo, B. garinii strain A87S,
B. anserina Ni-NL, B. hermsii HS1 and B. miyamotoi (LB-2001 and HT31). Blinded samples were examined by dark-field microscopy and 100
spirochetes per well were scored as either motile or immotile. Loss of motility in the NHS wells compared to HIS is indicative of complement
mediated killing and inactivation of spirochetes. The figure depicts the mean, and error bars represent the standard error of the mean of tripli-
cates from one representative experiment. A Kruskal-Wallis test was performed at t = 1 hour and t = 3 hours (p = 0.02 and 0.003, respectively) and
for each strain motility between NHS and HIS incubation was compared using a two-tailed Mann–Whitney test (no significant differences). This
experiment is representative of three different experiments. B. Growth inhibition assay. A total of 5x106 spirochetes per well of B. miyamotoi
LB-2001, B. miyamotoi HT31 or B. anserina Ni-NL were subjected to 50% NHS or HIS in the presence of a pH indicator (phenol red), cultivated at
33°C and absorbance at 562/630 nm was measured daily. A decrease in OD562/630 indicates decreasing pH due to spirochete growth. Error bars
represent mean ± standard error of the mean (triplicates). This experiment is representative of two different experiments. The OD562/630 of
spirochetes subjected to NHS versus HIS was compared using a repeated measures analysis of variance (ANOVA), and the p-value for interaction
is depicted for each strain.
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In this study we describe a culture medium and method
that can be easily used to culture B. miyamotoi. We were
able to passage B. miyamotoi for more than 10 times
under regular Borrelia burgdorferi culturing conditions, as
well as in culture plates, in a modified Kelly-Pettenkofer
medium with 10% added fetal calf serum (MKP-F). In-
dependently of our efforts, other groups are developing
alternative culture methods for B. miyamotoi (personal
communication Volker Fingerle). Using our culture
method, we discovered that B. miyamotoi is resistant to
human serum. This means that B. miyamotoi can evade
the human complement system, probably by using com-
plement regulating surface proteins similar to other
serum resistant Borrelia species. This evasion might
partly explain the fact that humans can be infected with
this spirochete, which seems to have adapted to humans
as a host.
B. hermsii, another invasive relapsing fever spirochete,
was first isolated by Kelly in 1971 [22] and his medium
formed the basis for later Lyme borreliosis culture
media. In 1982 Stoenner enriched this formulation, by
adding CMRL (without glutamine) and yeastolate [23].
Barbour further adjusted the “fortified Kelly’s medium”to form BSK-I medium, using neopeptone as the pep-
tone source and HEPES for buffering, while using CMRL
1066 with glutamine and omitting yeastolate [24]. In 1984
the medium was further improved to BSK-II medium by
adding yeastolate and again omitting glutamine [25]. In
1986 researchers from the Max von Pettenkofer Institute
altered the BSK media to culture B. burgdorferi sensu lato
in what they called “modified Kelly medium”, and later re-
ferred to as “modified Kelly-Pettenkofer medium”, MKP
medium [26]. Besides more subtle differences, MKP
medium differs from BSK-I and BSK-II medium by the ab-
sence of glutamine and yeastolate, respectively. The simi-
larity to these media is reflected by comparable isolation
rates of B. burgdorferi sensu lato in MKP compared to
BSK-II medium [27-29]. Because of previous observations
that B. miyamotoi could not be serially passaged in vitro
using BSK-II medium, in this study we cultured B. miya-
motoi in MKP medium with the addition of 10% fetal calf
serum, in an attempt to enhance growth of the pathogen.
However, other formulations might also be suitable for
culturing B. miyamotoi. Indeed, one might hypothesize
that the addition of other serum types also results in suc-
cessful cultivation, and we do not exclude the possibility
that existing culture media can be adjusted to allow for B.
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serum. Regardless, in MKP-F, both strains showed robust
replication in serial passages, and during the preparation
of this manuscript we have been able to culture both
strains for 15 passages without any loss in viability or peak
densities (data not shown). Thus, using our formulation,
we were able to culture two tick-derived B. miyamotoi iso-
lates, but it still needs to be assessed whether our or other
formulations are suitable for isolating the spirochete from
clinical specimens, and what the exact role of fetal calf
serum is in the in vitro propagation of B. miyamotoi. We
did attempt to isolate B. miyamotoi from 350 μl of CSF
from a patient who had a B. miyamotoi meningoencephal-
itis [9], however, this did not result in a positive culture,
probably due the fact that the sample had been stored
at −80°C for two years without the presence of glycerol.
Culture efforts on fresh patient materials should be
attempted in order to yield clinical isolates in the future.
Serum resistance is important in host invasiveness and
reservoir host range for Borrelia spirochetes [11,30]. B.
anserina, B. hermsii and B. miyamotoi are phylogenetic-
ally related Borrelia species [31,32]. We hypothesized that
similar to B. hermsii, B. miyamotoi would be serum resist-
ant, as these are both relapsing fever spirochetes able to
infect humans, and Borrelia anserina to be serum sensi-
tive. B. anserina is carried by Argas ticks which normally
feed on birds and some species of which can cause ana-
phylactic reactions upon occasional human bites [33,34].
Indeed, here we show that B. miyamotoi is serum resist-
ant, whereas B. anserina is sensitive to human serum. B.
anserina will probably have adapted to bird complement,
as it is able to cause avian borreliosis [35], however, to our
knowledge this remains to be investigated. Interestingly, a
previous study showed that this spirochete was unable to
bind human factor H, in contrast to B. hermsii [36]. This
underscores the importance of factor H binding in serum
resistance and host invasiveness. During the preparation
of this manuscript another group has identified B. miya-
motoi strain HT31 to be resistant to human complement,
confirming the phenotype described in this paper [37].
More research is needed to identify the mechanism behind
the complement resistance of B. miyamotoi, and we are
currently investigating whether B. miyamotoi spirochetes
express Complement Regulator Acquiring Surface Pro-
teins (CRASPs).
Our culture method will further facilitate whole gen-
ome sequencing of B. miyamotoi strains including its
plasmids as well as in vitro assays. In addition, the cul-
ture method described will be an impetus to basic and
clinical research on this emerging human pathogen.
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